Vertex Pharmaceuticals Incorporated
VRTX
$435.52
$1.500.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.50% | 6.66% | |||
| Total Other Revenue | -- | 107.00% | |||
| Total Revenue | 3.77% | 7.02% | |||
| Cost of Revenue | 0.48% | 3.22% | |||
| Gross Profit | 6.66% | 10.60% | |||
| SG&A Expenses | 4.83% | 7.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.50% | 4.11% | |||
| Operating Income | 7.33% | 11.94% | |||
| Income Before Tax | 1.23% | 75.66% | |||
| Income Tax Expenses | -13.67% | 197.38% | |||
| Earnings from Continuing Operations | 4.84% | 59.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.84% | 59.82% | |||
| EBIT | 7.33% | 11.94% | |||
| EBITDA | 7.21% | 11.71% | |||
| EPS Basic | 5.29% | 59.94% | |||
| Normalized Basic EPS | 6.18% | 11.71% | |||
| EPS Diluted | 5.26% | 60.24% | |||
| Normalized Diluted EPS | 6.25% | 11.89% | |||
| Average Basic Shares Outstanding | -0.43% | -0.08% | |||
| Average Diluted Shares Outstanding | -0.50% | -0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||